Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now
well recognized that asthma is a chronic inflammatory disease of the airways. The …

Purpose Omalizumab is the preferred add-on therapy for patients with moderate-to-severe
persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities …

Background Omalizumab has demonstrated efficacy in clinical trials of patients with asthma,
but real-world data are needed. Objective To assess outcomes after omalizumab initiation in …

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐
IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent …

Objective. The 2007 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines
shifted the focus of care from asthma severity to ongoing assessment of asthma control …

Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using
data from a multicenter registry of severe asthma, we evaluated and compared the clinical …

Background Patients included in clinical trials do not necessarily reflect the real-world
population. Objective To understand the characteristics, including disease and comorbidity …

Background Omalizumab is a non-steroidal medication indicated for the treatment of poorly
controlled moderate-to-severe allergic asthmatics. This observational study examines the …

Background When first approved in the European Union (EU), the omalizumab dosing table
had upper bodyweight and IgE limits of 150 kg and 700 IU/mL, respectively. In this study, we …

Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the
IgE indicated in Europe for the treatment of severe persistent allergic asthma, inadequately …